There are 37 resources available
LBA66 - Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)
Presenter: Satoru Miura
Session: Proffered Paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA63 - SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hossein Borghaei
Session: Proffered Paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA65 - KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Presenter: Marina Garassino
Session: Proffered Paper session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA56 - Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
Presenter: Jonathan Spicer
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1261O - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
Presenter: Mark Awad
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA4 - Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Presenter: Herbert Ho Fung Loong
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA5 - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
Presenter: Nicolas Girard
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
1687O - PRIMCAT: A novel approach to informing health technology assessment decision making in Australia
Presenter: Fanny Franchini
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Presenter: Aaron Lisberg
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
LBA14 - Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
Presenter: Byoung Chul Cho
Session: Presidential 3
Resources:
Abstract
Slides
Webcast